SpyGlass Pharma, Inc. (SGP)
| Market Cap | 1.23B |
| Revenue (ttm) | n/a |
| Net Income | -56.05M |
| EPS | -3.88 |
| Shares Out | 33.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,374 |
| Open | 34.50 |
| Previous Close | 34.08 |
| Day's Range | 33.92 - 37.12 |
| 52-Week Range | 17.06 - 37.12 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 44.00 (+19.73%) |
| Est. Earnings | Nov 17, 2026 |
About SGP
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for SGP stock is "Strong Buy." The 12-month stock price target is $44.0, which is an increase of 19.73% from the latest price.
News
SpyGlass Pharma to Participate in Upcoming Investor Conferences
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the exec...
SpyGlass announces four-year FIH Bimatoprost Drug Pad-IOL System trial results
SpyGlass Pharma (SGP) announced four-year first-in-human, or FIH, trial results for the Bimatoprost Drug Pad-IOL System, or BIM-IOL System, in patients with mild-to-moderate open angle glaucoma, or OA...
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups 86% of patients remained off all topical IOP-lowering drops 90% of patients m...
SpyGlass Pharma acquires Advanced Vision Science for $13M in cash
SpyGlass Pharma (SGP) announced the acquisition of all the outstanding shares of common stock of Advanced Vision Science for approximately $13M in cash. This acquisition secures scalable commercial IO...
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of ...
SpyGlass Pharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A novel intraocular lens with integrated drug delivery targets a $13 billion market by simplifying glaucoma and cataract treatment in a single procedure, showing strong clinical efficacy and safety. Phase III trials are underway, with a potential launch in 2029.
SpyGlass Pharma Transcript: Citigroup’s Biopharma Back to School Summit 2026
A novel drug-eluting intraocular lens for cataract and glaucoma is in phase III trials, with strong early data showing long-term efficacy and streamlined surgical workflow. Market access is supported by new reimbursement codes, and a robust cash position funds development through launch. Four-year clinical data and a next-gen drug ring system trial are key near-term catalysts.
SpyGlass Pharma initiated with an Outperform at Raymond James
Raymond James analyst Christopher Raymond initiated coverage of SpyGlass Pharma (SGP) with an Outperform rating and $39 price target SpyGlass Pharma’s BIM-IOL offers a potentially differentiated glauc...
SpyGlass Pharma reports Q2 EPS (59c), consensus (55c)
“We are pleased to report that enrollment in our parallel Phase 3 registrational trials of the BIM-IOL System, which if approved by the US Food and Drug Administration, has the…
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. Bimatoprost-Drug Ring System (...
SpyGlass Pharma Earnings release: Q2 2026
SpyGlass Pharma released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
SpyGlass Pharma Quarterly report: Q2 2026
SpyGlass Pharma has published its Q2 2026 quarterly earnings report on August 6, 2026.
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shan...
SpyGlass Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
A novel intraocular lens system delivers long-term glaucoma therapy during cataract surgery, showing strong efficacy and safety in early trials. The product integrates into standard workflows, expands surgeon access, and has clear regulatory and reimbursement paths, with pivotal phase III data and commercialization milestones expected through 2029.
SpyGlass Pharma Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a combined cataract and glaucoma treatment with a three-year drug-eluting intraocular lens, showing superior IOP reduction and high patient retention without additional therapy. A second-generation removable drug ring system is in early trials, and strong financials support operations through 2028.
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as ...
SpyGlass Pharma Slides: Corporate presentation
SpyGlass Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
SpyGlass Pharma Transcript: Stifel 2026 Virtual Ophthalmology Forum
Significant progress includes timely phase III trial enrollment, strong long-term efficacy data, and a clear regulatory and reimbursement strategy. Upcoming milestones feature new clinical trials and key data readouts, with positive surgeon feedback and streamlined policy positioning.
SpyGlass Pharma granted new CPT code for lens system
SpyGlass Pharma (SGP) announced that the American Medical Association’s CPT Editorial Panel approved a new add-on Category III CPT code for attachment and insertion of intraocular lens prosthesis-moun...
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Associati...
SpyGlass Pharma Slides: Corporate presentation
SpyGlass Pharma has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highl...
SpyGlass Pharma Earnings release: Q1 2026
SpyGlass Pharma released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
SpyGlass Pharma Quarterly report: Q1 2026
SpyGlass Pharma has published its Q1 2026 quarterly earnings report on May 14, 2026.
SpyGlass Pharma Slides: Corporate presentation
SpyGlass Pharma has posted slides in relation to its latest quarterly earnings report, which was published on April 9, 2026.